Melanoma Clinical Trials in New York

Showing 281-300 of 341 trials

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

NCT00003715

RATIONALE: Vaccines made from a person's melanoma cells may make the body build an immune response to kill tumor cells. Interferon alfa may interfere with the growth of the cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of melanoma vaccine with that of interferon alfa-2b in treating patients who have stage III melanoma that has spread to regional lymph nodes following surgery.

Melanoma (Skin)

AVAX Technologies425 participantsStarted Dec 1998

Rancho Mirage, California, United States • New Haven, Connecticut, United States • North Miami Beach, Florida, United States +14 more locations

COMPLETEDPhase 3< 1 mile

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00110019

This randomized phase III trial studies carboplatin, paclitaxel, and sorafenib tosylate to see how well they work compared to carboplatin and paclitaxel in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether giving carboplatin and paclitaxel together with sorafenib tosylate is more effective than carboplatin and paclitaxel in treating melanoma.

Mucosal MelanomaRecurrent MelanomaStage IIIA Skin Melanoma+3 more

National Cancer Institute (NCI)823 participantsStarted Jun 2005

Birmingham, Alabama, United States • Fort Smith, Arkansas, United States • Little Rock, Arkansas, United States +216 more locations

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Melanoma Trials in Other Cities

Phase II, 2nd Line Melanoma - RAND Monotherapy

CCI-779 in Treating Patients With Metastatic Melanoma

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in New York